Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma

PURPOSE: This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvajal, Richard D., Nathan, Paul, Sacco, Joseph J., Orloff, Marlana, Hernandez-Aya, Leonel F., Yang, Jessica, Luke, Jason J., Butler, Marcus O., Stanhope, Sarah, Collins, Laura, McAlpine, Cheryl, Holland, Chris, Abdullah, Shaad E., Sato, Takami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177239/
https://www.ncbi.nlm.nih.gov/pubmed/35254876
http://dx.doi.org/10.1200/JCO.21.01805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177239/
https://www.ncbi.nlm.nih.gov/pubmed/35254876
http://dx.doi.org/10.1200/JCO.21.01805

Ejemplares similares